Clinical Trials

250 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06970743 2026-04-22

CaDAnCe-303

150 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04224493 2026-04-20

SYMPHONY-1

555 enrolled

Lymphoma, Follicular

NCT04404283 2026-04-20

ECHELON-3

239 enrolled 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05139017 2026-04-20

waveLINE-003

Phase 2/3 Recruiting

290 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-04-20

MK-2140-011

594 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04884035 2026-04-17

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Phase 1 Recruiting

224 enrolled

Lymphoma, B-Cell

NCT05888493 2026-04-17

LEDA

109 enrolled

Phase 1 Not yet recruiting

Lymphoma, Follicular, Recurrence

NCT07226843 2026-04-17

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

360 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06717347 2026-04-16

MK-2140-010

1,046 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06651970 2026-04-15

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Phase 4 Recruiting

60 enrolled

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT06943872 2026-04-15

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

630 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06090539 2026-04-14

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Phase 1/2 Recruiting

308 enrolled

Lymphoma, Non-Hodgkin

NCT04623541 2026-04-13

EPCORE™ CLL-1

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05283720 2026-04-13

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06149286 2026-04-13

OLYMPIA-5

470 enrolled

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06191744 2026-04-13

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT06564038 2026-04-13

Soundtrack-E

Phase 1/2 Recruiting

408 enrolled

Phase 1/2 Not yet recruiting

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT07520006 2026-04-13

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

150 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04542824 2026-04-08

EPCORE™ NHL-3

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-04-08

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06230224 2026-04-08

OLYMPIA-4

216 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06508658 2026-04-08

EPCORE DLBCL-4

379 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07029737 2026-04-08

SOUND-MCL

55 enrolled

Lymphoma, Mantle-Cell

NCT04673617 2026-04-03

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

45 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT05533775 2026-04-03

iMATRIX GLO

Phase 1/2 Recruiting

65 enrolled

Recurrence

NCT06084936 2026-04-02

GLOBRYTE

182 enrolled

Lymphoma

NCT04824092 2026-04-01

frontMIND

899 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07409428 2026-04-01

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

240 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04529772 2026-03-31

ESCALADE

611 enrolled

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07139873 2026-03-27

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

250 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04384484 2026-03-24

LOTIS 5

440 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT07015242 2026-03-24

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

65 enrolled

Lymphoma

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence

NCT02947347 2026-03-17

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Phase 3 Completed

445 enrolled 18 charts

Phase 2 Not yet recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT07477366 2026-03-17

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

20 enrolled

Lymphoma, B-Cell

NCT05624554 2026-03-16

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

300 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05947851 2026-03-13

BELLWAVE-010

735 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06091254 2026-03-11

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT03336333 2026-03-09

SEQUOIA

590 enrolled 12 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05171647 2026-03-06

SUNMO

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT04075292 2026-03-05

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

155 enrolled 16 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04285567 2026-03-03

CRISTALLO

Phase 3 Completed

166 enrolled 27 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03930953 2026-02-19

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

438 enrolled

Lymphoma, Non-Hodgkin, Recurrence

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

635 enrolled 2 FDA

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT04980222 2026-02-17

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

46 enrolled

Lymphoma

NCT06356129 2026-02-12

GOLSEEK-1

850 enrolled

Lymphoma

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03274492 2026-02-06

POLARIX

1,000 enrolled 2 FDA